C3 Glomerulopathy: Pathogenesis And Treatment - PubMed

Full text links CiteDisplay options Display options Format AbstractPubMedPMID

Abstract

C3 glomerulopathy (C3G) is a rare set of kidney diseases with 2 patterns: C3 glomerulonephritis (C3GN) and dense deposit disease. Pathogenesis of both diseases is due to complement dysregulation in the alternative pathway. Acquired or genetic alterations of the regulatory proteins of the complement pathway result in C3G. Although the disease is characterized by low C3 levels in serum and C3-dominant staining by immunofluorescence on biopsy, other disease entities such as infection-related glomerulonephritis and masked monoclonal deposits can present similarly. Both the C3GN and dense deposit disease variants of C3G are progressive and recur in transplanted kidneys. Although no direct treatment is available, complement blockers are either available or in the clinical trial phase. This review will survey the pathogenesis of C3GN and current treatment options.

Keywords: Complement; Dense deposit disease; Membranoproliferative glomerulonephritis.

Copyright © 2019 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

PubMed Disclaimer

Similar articles

• C3 glomerulopathy and current dilemmas. Ito N, Ohashi R, Nagata M. Ito N, et al. Clin Exp Nephrol. 2017 Aug;21(4):541-551. doi: 10.1007/s10157-016-1358-5. Epub 2016 Nov 23. Clin Exp Nephrol. 2017. PMID: 27878657 Free PMC article. Review.
• C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, Radhakrishnan J, Marasa M, Rosenstiel PE, Herlitz LC, Markowitz GS, D'Agati VD, Appel GB. Bomback AS, et al. Kidney Int. 2018 Apr;93(4):977-985. doi: 10.1016/j.kint.2017.10.022. Epub 2018 Jan 6. Kidney Int. 2018. PMID: 29310824
• C3 glomerulonephritis with a severe crescentic phenotype. Ravindran A, Fervenza FC, Smith RJH, Sethi S. Ravindran A, et al. Pediatr Nephrol. 2017 Sep;32(9):1625-1633. doi: 10.1007/s00467-017-3702-8. Epub 2017 Jun 7. Pediatr Nephrol. 2017. PMID: 28593446
• Defining the complement biomarker profile of C3 glomerulopathy. Zhang Y, Nester CM, Martin B, Skjoedt MO, Meyer NC, Shao D, Borsa N, Palarasah Y, Smith RJ. Zhang Y, et al. Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1876-82. doi: 10.2215/CJN.01820214. Epub 2014 Oct 23. Clin J Am Soc Nephrol. 2014. PMID: 25341722 Free PMC article.
• C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis. Xiao X, Pickering MC, Smith RJ. Xiao X, et al. Semin Thromb Hemost. 2014 Jun;40(4):465-71. doi: 10.1055/s-0034-1376334. Epub 2014 May 5. Semin Thromb Hemost. 2014. PMID: 24799308 Review.

See all similar articles

Cited by

• Membranoproliferative Glomerulonephritis over 20 Years at a Tertiary Referral Center in the UK. O'Keeffe H, Storrar J, Ramakrishna C, Metaoy S, Chrysochou C, Chinnadurai R, Kalra PA, Sinha S. O'Keeffe H, et al. Glomerular Dis. 2024 Aug 2;4(1):159-166. doi: 10.1159/000540672. eCollection 2024 Jan-Dec. Glomerular Dis. 2024. PMID: 39473993 Free PMC article.
• Successfully treated C3 glomerulopathy in which protein and genetic analyses were useful for diagnosis. Kanzaki M, Kurahashi M, Watanabe K, Nishikawa M, Fukuoka K, Shimada N, Mizuno M, Asano K. Kanzaki M, et al. CEN Case Rep. 2024 Sep 12. doi: 10.1007/s13730-024-00928-5. Online ahead of print. CEN Case Rep. 2024. PMID: 39264532
• Updates on C3 Glomerulopathy in Kidney Transplantation: Pathogenesis and Treatment Options. Bartoli G, Dello Strologo A, Grandaliano G, Pesce F. Bartoli G, et al. Int J Mol Sci. 2024 Jun 13;25(12):6508. doi: 10.3390/ijms25126508. Int J Mol Sci. 2024. PMID: 38928213 Free PMC article. Review.
• Clinical and pathological features of 52 patients with glomerulonephritis with dominant C3. Wei J, Huang Y, Yuan S, Chen X, Fu X, Li Z, Li Y, Sun L, Liu H, Zhu X. Wei J, et al. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Jan 28;49(1):75-83. doi: 10.11817/j.issn.1672-7347.2024.230328. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024. PMID: 38615169 Free PMC article. Chinese, English.
• A Case of C3 Nephritis With a Rare Variant of the CFHR5 Gene. Kamido H, Yamamoto S, Yokoi H, Mizuno M, Yanagita M. Kamido H, et al. Cureus. 2024 Feb 27;16(2):e55102. doi: 10.7759/cureus.55102. eCollection 2024 Feb. Cureus. 2024. PMID: 38558633 Free PMC article.

See all "Cited by" articles

Publication types

• Review Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

MeSH terms

• Complement C3 / immunology* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Complement Inactivating Agents* / immunology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Complement Inactivating Agents* / pharmacology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Complement Pathway, Alternative* / drug effects Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Complement Pathway, Alternative* / immunology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Glomerulonephritis, Membranoproliferative* / immunology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Glomerulonephritis, Membranoproliferative* / physiopathology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Glomerulonephritis, Membranoproliferative* / therapy Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Humans Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Prognosis Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

Substances

• Complement C3 Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Complement Inactivating Agents Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

Related information

• Cited in Books
• MedGen

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Miscellaneous

  • NCI CPTAC Assay Portal